RenovoRx (RNXT) Competitors $1.00 +0.01 (+1.00%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.00 +0.00 (+0.50%) As of 05/2/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNXT vs. TLSA, NKTX, CHRS, LYEL, SCPH, LRMR, CTNM, KRRO, OGI, and EPRXShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Tiziana Life Sciences (TLSA), Nkarta (NKTX), Coherus BioSciences (CHRS), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Korro Bio (KRRO), Organigram (OGI), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Tiziana Life Sciences Nkarta Coherus BioSciences Lyell Immunopharma scPharmaceuticals Larimar Therapeutics Contineum Therapeutics Korro Bio Organigram Eupraxia Pharmaceuticals RenovoRx (NASDAQ:RNXT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations. Which has stronger earnings & valuation, RNXT or TLSA? RenovoRx has higher revenue and earnings than Tiziana Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRx$43K849.93-$10.23M-$0.39-2.56Tiziana Life SciencesN/AN/A-$17.69MN/AN/A Does the MarketBeat Community prefer RNXT or TLSA? Tiziana Life Sciences received 84 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 54.55% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformRenovoRxOutperform Votes1254.55% Underperform Votes1045.45% Tiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Does the media prefer RNXT or TLSA? In the previous week, RenovoRx had 4 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for RenovoRx and 1 mentions for Tiziana Life Sciences. RenovoRx's average media sentiment score of 0.19 beat Tiziana Life Sciences' score of 0.11 indicating that RenovoRx is being referred to more favorably in the media. Company Overall Sentiment RenovoRx Neutral Tiziana Life Sciences Neutral Is RNXT or TLSA more profitable? Tiziana Life Sciences' return on equity of 0.00% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -205.96% -110.01% Tiziana Life Sciences N/A N/A N/A Do insiders & institutionals have more ownership in RNXT or TLSA? 3.1% of RenovoRx shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, RNXT or TLSA? RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do analysts rate RNXT or TLSA? RenovoRx presently has a consensus price target of $7.00, suggesting a potential upside of 600.00%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRenovoRx beats Tiziana Life Sciences on 9 of the 14 factors compared between the two stocks. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.55M$6.85B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-1.757.4422.6918.83Price / Sales849.93257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book-3.576.576.794.33Net Income-$10.23M$143.14M$3.22B$247.97M7 Day Performance1.01%3.48%3.37%3.18%1 Month Performance9.89%10.49%6.95%8.13%1 Year Performance-18.03%-3.31%16.13%5.01% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx2.1798 of 5 stars$1.00+1.0%$7.00+600.0%-21.3%$36.55M$43,000.00-1.756Gap UpTLSATiziana Life Sciences0.3622 of 5 stars$1.13+5.6%N/A+81.5%$132.04MN/A0.008Short Interest ↑Gap DownNKTXNkarta2.8011 of 5 stars$1.85+2.2%$14.86+703.1%-72.2%$131.27MN/A-0.98140Upcoming EarningsPositive NewsCHRSCoherus BioSciences3.5616 of 5 stars$1.06-5.4%$5.38+407.1%-49.3%$129.81M$266.96M-13.25330Upcoming EarningsAnalyst ForecastNews CoverageGap DownLYELLyell Immunopharma3.4067 of 5 stars$0.44+0.9%$1.00+128.5%-80.8%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoverageSCPHscPharmaceuticals3.6059 of 5 stars$2.56-0.4%$14.00+446.9%-44.2%$128.73M$36.33M-1.3530Positive NewsLRMRLarimar Therapeutics1.7345 of 5 stars$2.01+5.2%$19.63+876.4%-61.0%$128.70MN/A-1.7530Earnings ReportUpcoming EarningsOptions VolumeAnalyst RevisionNews CoveragePositive NewsCTNMContineum Therapeutics2.1857 of 5 stars$4.95+7.1%$24.80+401.0%-72.5%$128.07M$50M-1.0131KRROKorro Bio1.6432 of 5 stars$13.64-1.9%$120.43+782.9%-64.1%$128.07M$2.27M-1.4570Analyst UpgradeAnalyst RevisionNews CoverageOGIOrganigram0.4162 of 5 stars$1.00-6.5%N/A-38.8%$126.26M$166.12M-2.63860Positive NewsEPRXEupraxia Pharmaceuticals2.9341 of 5 stars$3.48+5.8%$10.50+201.7%+44.3%$124.76MN/A-4.8329Positive NewsHigh Trading Volume Related Companies and Tools Related Companies TLSA Alternatives NKTX Alternatives CHRS Alternatives LYEL Alternatives SCPH Alternatives LRMR Alternatives CTNM Alternatives KRRO Alternatives OGI Alternatives EPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNXT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
